|
業務類別
|
Biotechnology |
|
業務概覽
|
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection. |
| 公司地址
| 225 Franklin Street, Suite 2100, Boston, MA, USA, 02110 |
| 電話號碼
| +1 857 284-8891 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ateapharma.com |
| 員工數量
| 55 |
| Ms. Andrea J. Corcoran |
Chief Financial Officer, Secretary, Executive Vice President, Legal |
美元 549.53K |
27/04/2026 |
| Dr. Jean-Pierre Sommadossi,PhD |
President, Chief Executive Officer and Chairman of the Board |
美元 703.49K |
27/04/2026 |
| Mr. Wayne Foster |
Chief Accounting Officer and Executive Vice President, Finance |
-- |
27/04/2026 |
| Dr. Janet Hammond, M.D.,PhD |
Chief Development Officer |
美元 590.89K |
27/04/2026 |
| Dr. Maria Arantxa Horga, M.D. |
Chief Medical Officer |
美元 523.64K |
27/04/2026 |
| Mr. John Vavricka |
Chief Commercial Officer |
美元 443.17K |
27/04/2026 |
|
|
| Dr. Howard Berman, PhD |
Independent Director |
27/04/2026 |
| Mr. Franklin M. Berger, C.F.A. |
Lead Independent Director |
27/04/2026 |
| Dr. Jean-Pierre Sommadossi,PhD |
President, Chief Executive Officer and Chairman of the Board |
27/04/2026 |
| Dr. Bruce Polsky, M.D. |
Independent Director |
27/04/2026 |
| Ms. Barbara G. Duncan |
Independent Director |
27/04/2026 |
| Mr. Bruno Lucidi |
Independent Director |
27/04/2026 |
| Dr. Polly A. Murphy, D.V.M.,PhD |
Independent Director |
27/04/2026 |
| Dr. Jerome M. Adams, M.D. |
Independent Director |
27/04/2026 |
| Mr. Arthur Kirsch |
Independent Director |
27/04/2026 |
|
|
|
|
